Yin Jin, Cai Xiaoya, Qian Bingxin, Liu Ying, Li Dengju
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Med. 2024 Dec;13(24):e70515. doi: 10.1002/cam4.70515.
The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost-efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short-course blinatumomab treatment for R/R Ph- B-ALL at our center.
Blinatumomab was administered with 24-h continuous intravenous infusion (9 μg/day for the first 3 days and 28 μg/day for 6-10 days). The clinical data of 30 R/R B-ALL patients were collected and analyzed.
A total of 25 patients (83.3%) including 13 (43.3%) with a high leukemic load (> 50%) achieved morphological CR. Twelve patients (40%) were MRD-negative. The estimated 2-year OS rate was 82.62%. The 2-year PFS rate was 78.35%. The estimated 2-year OS and PFS were significantly better in patients receiving further treatment.
Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost-efficiency and resource management in health care.
在中国，全剂量全程使用博纳吐单抗的高昂费用导致大多数患者减少剂量并缩短治疗周期。鉴于当前医疗保健中对成本效益和资源管理的需求，我们回顾性评估了我院短疗程博纳吐单抗治疗复发/难治性Ph- B-ALL的临床效果。
博纳吐单抗采用24小时持续静脉输注给药（前3天为9μg/天，第6 - 10天为28μg/天）。收集并分析30例复发/难治性B-ALL患者的临床资料。
共有25例患者（83.3%）达到形态学完全缓解，其中13例（43.3%）白血病负荷高（>50%）。12例患者（40%）微小残留病呈阴性。估计2年总生存率为82.62%。2年无进展生存率为78.35%。接受进一步治疗的患者估计2年总生存率和无进展生存率显著更高。
我们的研究结果为博纳吐单抗治疗的优化提供了新见解，提出了一种可行的治疗方案，符合当前医疗保健中对成本效益和资源管理的需求。
